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SUMMARY 
 
We showed previously that exogenous overexpression of C3G, a guanine nucleotide releasing factor 
(GEF) for Rap1 and R-Ras proteins, blocks the focus-forming activity of cotransfected, activated, sis, ras 
and v-raf oncogenes in NIH 3T3 cells. In this report, we show that C3G also interferes with dbl and R-Ras 
focus forming activity and demonstrate that the transformation suppressor ability of C3G maps to its Crk-
binding region (SH3-b domain). Using full-length C3G and C3GΔCat mutant, lacking catalytic domain, 
we showed here that overexpression of cotransfected C3G or C3GΔCat inhibited oncogenic Hraslys12-
mediated phosphorylation of ERK, without altering Ras and Raf-1 kinase activation. We also showed that, 
overexpressed C3G and C3GΔCat inhibited viability of oncogenic Ras-induced colonies in soft agar, 
indicating that C3G interferes with the anchorage-independent growth of Ras-transformed cells in a Rap1-
independent manner. Consistent with both observations, overexpression of exogenous C3G and C3GΔCat 
also caused downregulation of Ras-induced cyclin A expression. All together, our results indicate that 
C3G interferes with at least two separate aspects of oncogenic transformation -cell cycle progression and 
loss of contact inhibition-, and that these inhibitory effects probably account for its transformation 
suppressor activity. 
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INTRODUCTION 
 
The C3G gene product is a modular protein acting as an exchange factor for the Rap and R-Ras 
proteins in fibroblasts (Gotoh et al., 1995; Gotoh et al., 1997; Ohba et al., 2000). C3G binds to the N-
terminal SH3 domain of the adaptor protein Crk through four proline-rich stretches encompassing the 
central region of the molecule (residues 282-616 of the human protein) (Knudsen et al., 1994; Tanaka et 
al., 1994). The C3G molecule also encompasses CDC25-H and REM domains characteristic of the GEFs 
for the Ras family of proteins (Quilliam et al., 2002).  
C3G is activated by multiple signals depending on the cell type (McLeod et al., 1998; Reedquist and 
Bos, 1998; Sakkab et al., 2000; Yokote et al., 1998; York et al., 1998; Zhu et al., 1998) and also can act as 
a mediator in the activation of several pathways, including the JNK, ERK and Rac signaling pathways 
(Mochizuki et al., 2000; York et al., 1998) (Abassi and Vuori, 2002; Ishimaru et al., 1999). 
C3G signaling also plays a crucial role in integrin-mediated cell adhesion and migration (Arai et al., 
2001; Arai et al., 1999; de Jong et al., 1998; Uemura and Griffin, 1999), assembly and stabilisation of 
focal adhesion (Li et al., 2002; Voss et al., 2003) and vascular myogenesis (Voss et al., 2003), a function 
that probably involves activation of Rap1 or R-Ras (Arai et al., 2001; Arai et al., 1999; de Jong et al., 
1998; Uemura and Griffin, 1999). In fact, disruption of C3G expression in mice affects adhesion and 
spreading of embryonic fibroblasts (Ohba et al., 2001). Cell adhesion plays an essential role in regulating 
proliferation during the G1 phase of the cell cycle, and loss of substrate adhesion is a requirement for 
oncogenic transformation (Guadagno et al., 1993). Oncogenic Ras induces anchorage-independent growth 
in rodent fibroblast cell lines, measured as the ability to form colonies in semisolid medium. It has been 
described that Ras drives cyclin A expression, a most critical step for induction of anchorage-independent 
growth by this oncogene (Yang et al., 1998). 
We have demonstrated previously that exogenously overexpressed C3G suppresses Ras-mediated 
transformation, an effect that appears to be independent of its CDC25-H, catalytic domain (Guerrero et al., 
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1998). The aim of this study was to map the specific region of C3G required for its transformation 
suppression activity and to determine the mechanisms by which C3G exerts such an effect. Here we show 
that the Crk-binding domain is responsible for the transformation suppression ability of C3G, and that this 
is not exclusive of Ras-mediated pathways but seems to be a more general mechanism affecting other 
oncogenes like dbl or R-ras. Our data suggest that the mechanism of suppression involves inhibition of 
Ras-dependent ERK activation, and cyclin A expression. Furthermore, such an inhibitory effect is 
accompanied by a decrease in viability of cells in non-adherent conditions. Therefore, at least two aspects 
of oncogenic transformation, cell cycle regulation and anchorage-independent growth, are altered by 
overexpression of C3G.  These alterations may account, at least in part, for the inhibitory effect of C3G on 
oncogene-mediated transformation of NIH 3T3 fibroblasts. 
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RESULTS 
 
Transformation suppressor activity of C3G maps to its SH3-binding domain. 
We have previously shown that the transformation suppressor activity of C3G on sis, ras and raf 
oncogenes was independent of its catalytic domain (Guerrero et al., 1998). To further characterize the 
C3G region responsible for the suppression effect, we constructed additional deletion mutants including 
ΔNC3G (lacking the first 636 nucleotides of the gene) and C3GSH3-b (containing only the Crk-binding 
region; n625-n1982) which were cloned into mammalian expression vector pLTR2 (DiFiore et al., 1987) 
(Figure 1a).  These constructs were transfected into NIH 3T3 cells alone or in combination with a Neo-
selectable construct expressing oncogenic H-ras (pMEXneo Hraslys12, (Benito et al., 1991)). Transfectants 
were selected with G418 and/or HAT/gpt according with plasmid combinations.  Protein extracts from 
NIH3T3 cells cotransfected with Ras and these new C3G constructs and selected for double resistance 
(neo+gpt), showed a high level of expression of both C3G clones and Hraslys12 peptides (Figure 1b). We 
observed in several independent experiments that both the ΔNC3G and the C3GSH3-b constructs were 
able to decrease about 40-75% the number of Ras-induced foci (Figure 1c,d), a reduction similar to that 
observed with pLTR2C3G and pLTR2C3GΔCat constructs (Figure 1c) (Guerrero et al., 1998). These 
results confirmed that the SH3-b region is necessary for C3G to exert its transformation suppressor 
activity. 
 
C3G suppresses the transforming ability of dbl and R-ras oncogenes. 
To determine whether the transformation suppressor effect of C3G is limited to components of Ras-
dependent pathways or it involves more general mechanisms, we studied the effect of our C3G mutant 
constructs on dbl and R-ras cotransfected oncogenes. Figures 2 a,b show that C3G was also able to inhibit 
foci formation by these two oncogenes and that, as for ras, raf and sis, this effect was mediated by the 
SH3-b domain. Likewise, as observed with Ras (Guerrero et al., 1998), constructs in which the catalytic 
domain had been eliminated (C3GΔCat) showed an even higher inhibitory effect than the complete C3G 
Fig. 1 
Fig. 2 
 6 
over R-ras and dbl induced transformation (Figure 2a, b). Expression of both proteins was monitored by 
Western blotting (data not shown). These results indicate that the suppressor activity of C3G is not 
restricted to Ras pathways but it seems to involve a more general mechanism. 
 
C3G does not affect Ras, Raf-1 and MEK-1 activation.  
Results from our previous work (Guerrero et al., 1998) indicated that C3G blocked malignant 
transformation triggered by components of the Ras-Raf pathway. Thus, a first question is whether C3G 
directly affects Ras and/or Raf-1 activities. We performed Ras activity assays on cells permanently 
transfected with C3G, alone or in combination with oncogenic ras. Figure 3a showed that the presence of 
C3G did not affect the amount of Ras-GTP complex present in cells treated with FBS for various periods 
of time. Furthermore, regarding Raf-1, we also showed in transient tranfections that C3G did not affect 
either the mobility shift due to Raf-1 phosphorylation (Figure 3b). Since Raf-1 can be phosphorylated 
either for activation or for inhibition (Dhillon et al., 2002; Marais et al., 1995; Sozeri et al., 1992), to 
ensure that C3G is not affecting Raf-1 activity we studied, in permanently transfected clones, the 
phosphorylation status of MEK1, a known Raf-1 substrate, using an anti phosphoMEK1 antibody that 
specifically recognizes the serine residues (ser217 and ser221) phosphorylated by Raf-1. Figure 3c 
showed that C3G did not affect Raf-1-dependent MEK1 phosphorylation, suggesting that, as with Ras, 
Raf-1 activity is not altered by C3G. 
 
C3G expression inhibits Ras-induced ERK phosphorylation. 
To gain further insight into the mechanism of suppression, and given that both Ras and Raf are 
components of the ERK/MAPK pathway, we studied whether C3G affects Ras-mediated ERK activation, 
measured as p44/42 ERK phosphorylation. Permanently transfected clones expressing C3G and Hraslys12, 
alone or in combination, were starved for 20 h and stimulated for 5 minutes with 10% FBS or 25 ng/ml 
PDGF before determination of the levels of phosphorylated ERK. Figure 4a showed that oncogenic H-
Ras-mediated phosphorylation of ERK is inhibited in clones expressing C3G. We confirmed this result in 
Fig. 3 
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transiently transfected cells with the same DNAs. Figure 4b showed that the levels of Ras-mediated ERK 
phosphorylation decreases both in starved and exponentially growing cells that transiently overexpress 
C3G. This inhibitory effect was not Rap1 or R-Ras-mediated since C3GΔCat mutant, lacking the catalytic 
domain, also exhibited the same effect on ERK activation (Figure 4c). 
 
C3G alters anchorage-dependent properties of fibroblast cells  
We have previously shown that C3G does not affect NIH 3T3 cells viability in adherent conditions, 
and that C3G expressing cells exhibit a similar growth rate to cells transfected with vector alone (Guerrero 
et al., 1998). Besides faster growth, another indicator of tumorigenicity is the ability of transformed cells 
to form colonies in semisolid medium. Thus, we studied whether C3G may affect anchorage-independent 
growth of oncogenic Ras-expressing cells. NIH 3T3 clones expressing C3G, C3GΔCat or  Hraslys12 alone 
or in combination, were seeded in soft agar as described in Materials and Methods, and the number and 
size of resulting, growing colonies was determined. Figure 5 showed that expression of C3G and 
C3GΔCat reduced dramatically the growth (measured as the size of the colonies and the number of 
colonies larger than ~3000 µm3) of Ras-induced proliferating colonies in soft agar which is in 
concordance with its suppression role. This result clearly indicate that C3G exerts a strong inhibitory 
effect over the ability of Ras transformed cells to grow in soft agar independently of its exchange activity. 
The above results suggest that C3G expressing cells may display higher substrate dependence, and 
that C3G may confer augmented adhesive properties to the cells. To study this hypothesis, and based on 
recent reports showing that C3G plays an essential role for adhesion to laminin and gelatin (Voss et al., 
2003) we studied the adhesiveness of C3G and C3GΔCat expressing cells using laminin-1 coated wells. 
Figure 6 showed that ectopic expression of C3G increases ~40% to 60% the adhesion to laminin-1 of wild 
type NIH 3T3 cells or cells cotransfected with Hraslys12. However, expression of C3GΔCat mutant did not 
increase the adhesion to laminin. These results indicate that the higher adhesiveness conferred by 
overexpression of C3G is Rap1-dependent and does not account for the transformacion suppression effect 
on oncogenic transformation.  
Fig. 4  
Fig.  6 
Fig.  5 
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Effects of C3G on cell cyclin A expression 
Mitogenic signals promote G1 phase entry and cell cycle progression (Peeper et al., 1997), which is 
regulated by cyclin-CDKs complexes (Takuwa and Takuwa, 2001). The levels of most CDKs are 
relatively constant during the cell cycle (Yam et al., 2002); thus, the regulation of CDKs activities must be 
dependent of the corresponding cyclins.  Since cyclin A is essential for anchorage independent growth and 
its expression is regulated by Ras (Kang and Krauss, 1996; Takuwa and Takuwa, 2001; Yang et al., 1998), 
we studied whether C3G affects cyclin A expression. NIH 3T3 clones expressing C3G and/or Hraslys12 
were grown exponentially and the levels of cyclin A determined by immunoblotting. Figure 7 showed that 
Ras-induced cyclin A expression was clearly inhibited by both C3G and C3GΔCat overexpression, which 
is consistent with the inhibitory effect of C3G or C3GΔCat  on Hraslys12-mediated growth in suspension. 
Other cell cycle components studied like cyclin D and cyclin E were not altered by C3G (data not 
showed). 
Fig.  7 
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DISCUSSION 
 
Previously, we have shown that overexpression of transfected C3G suppresses oncogenic 
transformation mediated by cotransfected Ras oncogenes in NIH 3T3 fibroblasts. We also observed that 
such suppression was independent of the presence of the CDC25-H, catalytic, domain in the transfected 
C3G constructs (Guerrero et al., 1998). In the present work we have demonstrated that the C3G region 
responsible for this effect maps to its amino-terminal, SH3-binding domain.  Such an observation suggests 
that Rap1 (a small GTPase activatable by C3G), in spite of its previous depiction as a Ras antagonist 
(Sakoda et al., 1992), may not be the intermediary of the process of C3G-dependent suppression of 
transformation.  
We have also shown here that C3G inhibits focus formation induced not only by ras but also by the 
dbl and R-ras oncogenes.  This observation suggests that the suppressor function of C3G may involve 
more general mechanisms, not limited only to Ras oncogenes or pathways. The inhibitory effect on R-
Ras-mediated transformation is somewhat paradoxical, as R-Ras has also been described to be activated 
by C3G, although the GEF that exhibits highest exchange activity on R-Ras is Grf1 (Gotoh et al., 1997). It 
has to be mentioned that these published results refer to work using COS7 cells and thus the differences in 
cell type may account for some of these discrepancies. 
To get an insight into the suppression mechanism, and considering that malignant transformation by 
Ras is the result of the cooperation between various downstream pathways (Hamad et al., 2002; 
Rodriguez-Viciana et al., 1997), we studied the effect of C3G on some of the Ras effectors. Our results 
showed that whereas C3G does not affect activation of either Ras, Raf-1 or MEK1, it clearly inhibits Ras-
induced ERK1/2 phosphorylation. The effect of C3G on Ras-mediated ERK activation was not due to the 
particular characteristics of the permanently transfected clones, as i) the clones used were, in fact, mass 
cultures of the corresponding permanent transfections and ii) we were able to confirm the results in 
transiently transfected cell cultures. Obviously, the observed effect was much lower under these 
conditions due to the limited transfection efficiency of NIH 3T3 cells (around 10%). In this case, we could 
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only observe the inhibitory effect of C3G on ERK activation in non-stimulated cells (both starved and 
serum-growing non-synchronic cultures), but not in growth factor-stimulated cells, probably due to the 
masking effect of the PDGF- or serum-dependent ERK activation on the 90% non-transfected cells. 
C3GΔCat mutant, lacking the catalytic domain, also inhibited Ras-mediated ERK activation which is in 
agreement with its transformation suppression effect (Guerrero et al., 1998) and confirms that ERK 
participates in the suppression mechanism. It should be mentioned here that C3G is only affecting the 
serum-mediated short term activation of ERK, since we have previously shown that sustained ERK 
activity is not altered (Guerrero et al., 1998).  
We have also observed that C3G but not C3GΔCat exert an inhibitory effect on the PI3K-Akt 
pathway, which suggest that this pathway seems not to be involve in the transformation suppression 
mechanism (data not shown). 
Ras induces anchorage-independent growth via multiple pathways, by down-regulating multiple 
adhesion-regulated cell cycle events, such as cyclin A expression (Guadagno et al., 1993; Kang and 
Krauss, 1996; Yang et al., 1998). Cyclin A is required for initiation and progression through S phase 
(Takuwa and Takuwa, 2001), and its expression is dependent on cell adhesion (Guadagno et al., 1993). In 
fact, only cells overexpressing cyclin A are able to cycle in suspension (Guadagno et al., 1993; Kang and 
Krauss, 1996; Schulze et al., 1996). This is in concordance with our results where cells expressing C3G 
and C3GΔCat showed lower levels of cyclin A and reduced ability to grow in suspension (Figs. 5,6,7). 
Thus, according to our results, C3G antagonizes cyclin A expression (probably through inhibition of 
ERK) an adhesion-regulated cell cycle event. Increased cyclin A expression has been detected in many 
tumors (Yam et al., 2002); thus, our results showing reduced expression of cyclin A in C3G and C3GΔCat 
expressing cells support the notion of C3G as a transformation suppressor gene by a mechanism that does 
not involve Rap1 activation. 
Our results are in agreement with previous work showing that the activation of ERK and some cell 
cycle events like cyclin A expression, are the key components involved in the ability of cells to growth in 
non-adherent conditions (Howe et al., 1998; Renshaw et al., 1997). These author showed that the 
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activation of ERK by MEK1, but not the assembly of focal adhesions or the phosphorylation of focal 
adhesion proteins is the critical step that is altered in cells growing in suspension. This is in concordance 
with our results where not only C3G, which may activate focal adhesion proteins via Rap1, but also 
C3GΔCat inhibit growth in soft agar. 
In conclusion, the results presented here indicate that C3G inhibits Ras-mediated oncogenic 
transformation, independently of its guanine nucleotide exchange activity, by interfering with the 
activation of the ERK pathway, which then results in inhibition of cyclin A expression and anchorage 
independent growth. In addition, our results also show an effect of C3G on other oncogenes, like dbl and 
R-ras, suggesting that the inhibitory effect of C3G on malignant transformation may involve more general 
mechanisms, probably affecting components of the cell adhesion machinery. Further studies are necessary 
to clarify the function and the mechanisms by which C3G exerts its inhibitory effect on oncogene-
mediated transformation. The fact that C3G inhibits ERK activity without affecting other components of 
the Ras-ERK pathway suggests the existence of putative effector molecule(s) able to interact with the Crk 
binding domain of C3G and thus inhibiting ERK activation by still unknown mechanism(s). An 
interesting possibility, consistent with the results reported here, would be the activation of a potential 
phosphatase(s) acting downstream of C3G, that might be responsible for the observed inhibition of ERK 
phosphorylation. Further studies will be necessary to identify such a hypothetical phosphatase, or any 
other potential effector(s) mediating the inhibitory role of C3G on oncogenic suppression. 
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MATERIALS AND METHODS 
 
Construction of expression vectors for the ΔNC3G and C3GSH3-b fragments. 
Construct ΔNC3G was made by deletion of the first 212 aa. of C3G. A PshAI-BamHI fragment 
containing nucleotides from n637 to n3248 (considering n1 the A in the first ATG codon) was subcloned 
into pSP72/EcoRV-BamHI, and subcloned again as a BglII-BamHI fragment into pCEVKZHA (Miki et 
al., 1989). From the new construct, the ΔNC3G fragment was transferred by XhoI-BglII digestion into 
pLTR2 XhoI-BamHI (DiFiore et al., 1987). 
C3GSH3-b domain was cloned into pLTR2 by PCR amplification of a fragment enclosing from 
amino acid 209 to 660, comprising all the polyproline sequences important for SH3-binding, using oligos  
AF33  (GCTCCTCGAGATGAAGCAGGGACGTCCGTC) and AF34 
(CTTCGGATCCCGACTGAGCCGACTCC), containing respectively a XhoI and a BamHI site. After 
checking for the absence of mutations by sequencing, the resulting fragment was cloned into pLTR2 by 
XhoI-BamHI digestion. 
 
Permanent transfections and quantitation of focus-forming activity. 
NIH3T3 cells were transfected by the calcium phosphate method (Chen and Okayama, 1987) and 
individual colonies isolated as described previously (Guerrero et al., 1998).  
Focus forming activity was quantified after the transfection experiments by growing transfected 
NIH3T3 cells in the absence of selection for two weeks. The plates were then stained with a Giemsa 
solution and the number of morphologically transformed foci was counted. 
 
Transient transfections 
NIH 3T3 cells were transiently transfected using FuGENE 6 Transfection Reagent (Roche Molecular 
Biochemicals). FuGene 6 was diluted in 300 µl serum-free medium and DNA added at a ratio 3:1 (18 µl 
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FuGENE: 6 µg DNA). After 15 min incubation, the mixture was added dropwise to 60-70% confluent 
cells in 100 mm plates. After 24 hour of incubation at 37ºC and 5% CO2, cells were serum-deprived for 
additional 24 hours and then treated with the corresponding agonists. 
DNAs used in the transfection experiments included the constructs described above (ΔNC3G and 
C3GSH3-b fragments cloned in the pLTR2 vector for gpt selection), as well as clones described in a 
previous work (Guerrero et al., 1998). Mammalian expression constructs of the different oncogenes were 
obtained from several sources: Hraslys12 in pMEXneo (Benito et al., 1991), dbl in pZIPneoSV (Eva and 
Aaronson, 1985), R-ras  in pMEXneo (Saéz et al., 1994). Plasmids pLTR2 (DiFiore et al., 1987) and 
pMEXneo (Benito et al., 1991) were used as control vectors in every transfection experiment. 
In all experiments (both in transient and permanent transfectants) cells were stimulated with 20% 
FBS (fetal bovine serum) for 5 min or 25 ng/ml PDGF (platelet derived growth factor) for 2 min. 
PD98059 (50 µM, 2h before agonists) was used as negative controls of ERK activation. 
 
Antibodies and immunological studies 
In this study we have used the following antibodies: anti C3G #1008 (Guerrero et al., 1998), anti 
C3G (C-19) and C3G (H-300), anti H-Ras (C-20), anti R-Ras (C-20), anti Dbl (3), anti Raf-1 (C-12), anti 
ERK-1 (K-23) and anti cyclin A (C-19) from Santa Cruz Biotechnologies (Santa Cruz, CA); anti Ras M90 
(Lacal and Aaronson, 1986); anti phospho-p44/42MAPK (thr202/tyr204) and anti phosphoMEK-1/2 
(Ser217/221) from Cell Signaling Technology, Inc. (Beverly, CA); anti MEK1 from PharMingen (San 
Diego, CA). 
First antibodies were used at 1 µg/ml for #1008 antibody, 2 µg/ml for M90 antibody or 0.2 µg/ml for 
the rest. Anti-mouse or anti-rabbit Horseradish Peroxydase conjugated antibodies (Amersham 
Biosciences, Uppsala, Sweden) were used as secondary antibodies. The authenticity of the signal was 
checked in parallel experiments in which the antibody was incubated for 30 minutes at room temperature 
with an excess of a specific blocking peptide (20-40 µg). Detection was performed using the ECL-western 
blot detection system (Amersham Biosciences).  
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Ras activity assays  
Cells were grown to confluence in 100-mm dishes and serum starved for 20-24 h followed by 
incubation with 10% fetal bovine serum (FBS) for the indicated times.  After treatment, cells were washed 
twice with cold PBS and the levels of Ras-GTP determined using a “Ras activation assay kit” (Upstate 
Biotechnology, Lake Placid, NY) as described previously (Guerrero et al., 2002). 
 
Raf-mobility shift assay 
Activated Raf-1 was detected by mobility shift assay on NIH 3T3 cells transiently transfected with 
C3G and/or Hraslys12, since phosphorylated Raf-1 shows a reduced electrophoretic mobility.  40µg protein 
were loaded onto a 8% gel and the amount of Raf-1 determined by inmunoblotting with anti Raf-1 (C-12) 
from Santa Cruz Biotechnologies (Paasinen-Sohns and Holtta, 1997). 
 
Soft agar assay 
Serial cell dilutions at 106, 105 and 104 cells/ml were mixed with 0.5% Noble Agar in 1X DMEM + 
10% CS (calf serum) supplemented with G418, Killer HAT or both (100 µl of cell suspension in 4 ml of 
the above mixture) and added to 60 mm plates containing 4 ml 1% Agar + 1X DMEM + 10% CS. Plates 
were incubated a 37ºC in a humidified incubator and fed once a week for 14 days with 200 µl 1 x DMEM 
+ 10% CS. Then, plates were stained with 1 ml of 0.005% Crystal Violet for more than 1 hour and 
colonies counted using a dissecting microscope. Size of colonies was measured as volume applying the 
equation  4/3 πr3, where r is the radius of foci. 
 
 
Cell adhesion assay 
Cell attachment was assayed in microtiter plates as described (Matter and Laurie, 1994), 
http://iprotocol.mit.edu/protocol/292.htm. Briefly, cells were tripsinized, diluted to 2.0 x 105/ml in serum-
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free medium, added to the wells (previously coated overnight at 4ºC with 40 µg/ml laminin-1) and placed 
in incubator for 30-60 min at 37º C and 5% CO2. BSA (1%) was used as negative control. Cells were fixed 
by incubation with freshly diluted 1% glutaraldehyde in PBS for 10 min at room temperature and stained 
with 100 ul/well of freshly filtered 0.1% crystal violet for 25 min. After washing the cells, the dye was 
eluted with 0.5% Triton X-100 and the absorbance measured at 595 nm. 
 
Statistical analysis 
Data are represented as mean ± SEM. As comparisons were made between two experimental groups 
an unpaired Student’s t test was used. Results were considered significant when p<0.05.  
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LEGENDS TO FIGURES 
 
Figure 1. Transformation suppressor activity of C3G maps to its SH3-b domain (a) Schematic 
representation of human C3G structure and deletion mutants of functional domains utilized in this work. 
REM: Ras, exchange motif; SH3-b: SH3-binding or Crk-binding domain; CDC25-H: catalytic or CDC25-
homology domain. (b) Expression of  Hraslys12, C3G and mutants ΔNC3G and C3GSH3-b in stable, double 
contransfectant NIH 3T3 clones. (c, d)  Effect of the different C3G mutants on Ras-mediated focus 
forming activity in NIH 3T3 cells. 4 micrograms of each C3G mutant, cloned in pLTR2, were 
contransfected with 0.1 micrograms of pMEXneoHraslys12. (d) Representative Giemsa-stained plates, 
showing the effect of ΔNC3G and C3GSH3-b mutants on the number of Ras-induced foci, and (c) 
histogram representing average number of Hraslys12-induced foci and SD corresponding to four 
independent experiments. Data are normalized to the average number of  pMEXneoHraslys12-induced foci 
(~20000 foci /pmol DNA) represented here as 100. *p<0.05; **p< 0.01  vs pLTR2 + pMEXneoHraslys12. 
 
Figure 2. Effect of the C3G mutants on R-ras- and dbl-mediated transformation.  (a). Effect of the 
different C3G mutants on R-ras-mediated transformation. 4 micrograms of each C3G mutant, cloned in 
pLTR2 were cotransfected with 5 micrograms of pMEXneoR-Ras. Representative Giemsa-stained plates 
showing the effect of the different mutants on the number of R-Ras-induced foci (upper panel) and 
histogram representing average number of R-ras-induced foci and SD corresponding to three independent 
experiments (lower panel). Data are normalized to the average number of  pMEXneoR-Ras-induced foci 
(~300 foci /pmol DNA) represented here as 100. *p<0.05; **p< 0.01 vs pLTR2 + pMEXneoR-Ras. 
 (b). Effect of C3G mutants on dbl-induced focus forming activity. 4 micrograms of each C3G mutant, 
cloned in pLTR2 were contransfected with 0.1 micrograms of pZIPNeoSV-Dbl. Representative Giemsa-
stained plates showing the effect of the different mutants on the number of  dbl-induced foci (upper panel) 
and histogram representing average number of dbl-induced foci and SD corresponding to three 
independent experiments (lower panel). Data are normalized to the average number of pZipNeoSV-Dbl-
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induced foci (~5000 foci /pmol DNA) represented here as 100. *p<0.05; **p< 0.01 vs pLTR2 + 
pZipNeoSV-Dbl. 
 
Figure 3. C3G does not inhibit Ras, Raf-1 or MEK-1 activation. (a) Starved NIH 3T3 cells 
overexpressing C3G and/or Hraslys12, were stimulated with 20% FBS (fetal bovine serum) at the indicated 
times and the levels of Ras-GTP determined. The panels are representative Western blots showing 
activated Ras (Ras-GTP) and total Ras proteins. (b) C3G does not change Raf-1 electrophoretical 
mobility. NIH 3T3 cells were transiently transfected with pLTR2 or pLTR2C3G (5 µg) in the presence or 
absence of pMEXneoHraslys12 (1 µg), serum-starved for 24 hours and then stimulated with PDGF 25 ng/ml 
for 2 min. Representative Western blot showing the levels and shift mobility of Raf-1 detected with an 
anti Raf-1 polyclonal antibody (see Materials and Methods). (c) C3G does not interfere with MEK1 
phosphorylation. MEK-1 phosphorylation was detected by inmunoblotting with anti phosphoMEK1 
antibodies in serum-starved permanent transfected clones treated with PDGF in the presence or absence of 
PD98059 (50 µg/ml 2h, before PDGF). PhosphoMEK1 blots were stripped and reblotted against total 
MEK1 protein. Upper and lower panels are representative Western blots showing phosphoMEK1 (p-
MEK1) and total MEK1 proteins respectively.  
 
Figure 4. C3G inhibits ERK phosphorylation. (a, c) NIH 3T3 clones permanently transfected with the 
indicated DNAs (pLTR2, pLTR2C3G, pLTR2C3GΔCat pMEXneoHraslys12), were serum-starved and 
treated with FBS or PDGF as indicated and the amount of phosphoERK (p-ERK) determined by 
inmunoblotting. PhosphoERK blots were stripped and reblotted for total ERK protein. Western blots 
showing levels of C3G, C3GΔCat and H-Ras proteins are also indicated. C3G levels were detected with 
antibody antiC3G (C-19) against the last 19 amino acids of C3G protein and C3GΔCat was detected with 
anti C3G (H-300) that recongnize the first 300 amino acids of the protein. C: serum-starved control. S: 
serum-growing cells. (b) Transient transfections of  NIH 3T3 cells with the indicated DNAs were serum-
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starved (C) or left with serum (S) and the amount of phosphoERK, H-Ras and C3G determined by 
inmunoblotting. All panels are representative Westerns of three independent experiments. 
 
Figure 5. C3G effect on Ras-induced anchorage-independent growth. C3G and C3GΔCat inhibits 
oncogenic Hraslys12-induced growth in soft agar. (a) Representative pictures of cell cultures transfected 
with the indicated DNAs growing in soft agar. (b) Mean ± SEM of two independent experiments 
indicating number of colonies which volume is ≥ 3000 µm3. * p<0.001 vs pLTR2 + Hraslys12 cells. (c) 
Volume of foci growing in soft agar. Values represent the mean ± SEM from two separate experiments in 
which at least 40 foci were measured. * p<0.001 vs pLTR2 + Hraslys12 . 
 
Figure 6. C3G increases cell adhesion to laminin. (a) Representative pictures of the corresponding 
permanent transfected clones attached to laminin-1. (b) Mean ± SEM of three independent experiments 
performed in quadruplicate, ** p <0.0001 vs pLTR2, # p < 0.001 vs pLTR2 + Hraslys12 .  
 
Figure 7. C3G effect on cyclin A expression. C3G overexpression affects cyclin A expression in 
permanent clones transfected with Hraslys12 , alone or in combination with C3G or C3GΔCat. The Western 
blot in this figure is representative of two separate independent experiments. S: cells growing in steady-
sate conditions. 
 







